

CITATION REPORT

List of articles citing

American Society of Hematology 2021 guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19

DOI: 10.1182/bloodadvances.2020003763
Blood Advances, 2021, 5, 872-888.

Source: <https://exaly.com/paper-pdf/79258280/citation-report.pdf>

Version: 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
263	Should COVID-19 be branded to viral thrombotic fever?. 2021 , 116, e200552		1
262	Dynamic profile and clinical implications of hematological and immunological parameters in COVID-19 patients. A retrospective study. 2021 , 10, 2518-2523		1
261	COVID-19 and SEPSIS. 2021 ,		2
260	Clinical presentation, disease course, and outcome of COVID-19 in hospitalized patients with and without pre-existing cardiac disease: a cohort study across 18 countries. 2021 ,		14
259	Prophylactic anticoagulation for patients in hospital with covid-19. 2021 , 372, n487		15
258	Clinical Management of Hypertension, Inflammation and Thrombosis in Hospitalized COVID-19 Patients: Impact on Survival and Concerns. 2021 , 10,		5
257	Treatment of COVID-19: a review of current and prospective pharmacotherapies. 2021 , 82, 1-9		7
256	Prophylaxis and treatment of COVID-19 related venous thromboembolism. 2021 , 133, 27-35		10
255	Clinical presentation, disease course and outcome of COVID-19 in hospitalized patients with and without pre-existing cardiac disease in a cohort study across eighteen countries.		2
254	Anticoagulant Treatment of COVID-19 as Early as Possible-Sulodexide and Perspectives. 2021 , 121, 849-853		2
253	Effect of Intermediate-Dose vs Standard-Dose Prophylactic Anticoagulation on Thrombotic Events, Extracorporeal Membrane Oxygenation Treatment, or Mortality Among Patients With COVID-19 Admitted to the Intensive Care Unit: The INSPIRATION Randomized Clinical Trial. 2021 , 325, 1620-1630		235
252	Non-aneurysmal subarachnoid haemorrhage in COVID-19-authors' reply to Kawada T. 2021 , 63, 835-836		
251	Use of low-molecular weight heparin, transfusion and mortality in COVID-19 patients not requiring ventilation. 2021 , 52, 772-778		2
250	Intermediate-Dose versus Standard-Dose Prophylactic Anticoagulation in Patients with COVID-19 Admitted to the Intensive Care Unit: 90-Day Results from the INSPIRATION Randomized Trial. 2021 ,		21
249	A Review of Thromboembolic Events in Hospitalized COVID-19 Patients. 2021 ,		
248	The Potency of Seaweed Sulfated Polysaccharides for the Correction of Hemostasis Disorders in COVID-19. 2021 , 26,		5
247	Coagulation factors directly cleave SARS-CoV-2 spike and enhance viral entry. 2021 ,		9

246	COVID-19: breaking down a global health crisis. 2021 , 20, 35	43
245	Pathogenesis and Management of COVID-19. 2021 , 11, 77-93	2
244	Sustained High D-Dimer in Outpatients Who Have Recovered from Mild to Moderate Coronavirus Disease 2019 (COVID-19). 2021 ,	3
243	Bleeding risk by intensity of anticoagulation in critically ill patients with COVID-19: A retrospective cohort study. 2021 , 19, 1533-1545	10
242	Clinical Guidance of Prevention of Venous Thromboembolism in COVID-19. 2021 , 32, 99-103	1
241	Direct-acting oral anticoagulants use prior to COVID-19 diagnosis and associations with 30-day clinical outcomes. 2021 , 205, 1-7	4
240	At a crossroads: coronavirus disease 2019 recovery and the risk of pulmonary vascular disease. 2021 , 27, 342-349	2
239	COVID-19 treatment combinations and associations with mortality in a large multi-site healthcare system. 2021 , 16, e0252591	9
238	Therapeutic versus prophylactic anticoagulation for patients admitted to hospital with COVID-19 and elevated D-dimer concentration (ACTION): an open-label, multicentre, randomised, controlled trial. 2021 , 397, 2253-2263	150
237	The Fight against COVID-19 on the Multi-Protease Front and Surroundings: Could an Early Therapeutic Approach with Repositioning Drugs Prevent the Disease Severity?. 2021 , 9,	3
236	A review of thromboembolic events in hospitalized COVID-19 patients. 2021 , 19, 47	6
235	External validation of the IMPROVE-DD risk assessment model for venous thromboembolism among inpatients with COVID-19. 2021 , 52, 1032-1035	4
234	Role of combining anticoagulant and antiplatelet agents in COVID-19 treatment: a rapid review. 2021 , 8,	7
233	Thrombosis in Covid-19 and non-Covid-19 pneumonia: role of platelets. 2021 , 32, 1009-1017	3
232	Widespread Parenchymal Abnormalities and Pulmonary Embolism on Contrast-Enhanced CT Predict Disease Severity and Mortality in Hospitalized COVID-19 Patients. 2021 , 8, 666723	2
231	Further Evidence Supporting the Use of Prophylactic Anticoagulation in Hospitalized Patients With COVID-19. 2021 , 4, e2112403	1
230	Anti-viral treatment for SARS-CoV-2 infection: A race against time amidst the ongoing pandemic. 2021 , 10, 100096	17
229	Potential Dexamethasone-Direct Oral Anticoagulant Drug Interaction: Is This a Concern in COVID?. 2021 , 10600280211025042	4

228	Standard prophylactic versus intermediate dose enoxaparin in adults with severe COVID-19: A multi-center, open-label, randomized controlled trial. 2021 , 19, 2225-2234	37
227	SARS-CoV-2 and Acute Cerebrovascular Events: An Overview. 2021 , 10,	2
226	COVID-19-associated coagulopathy and antithrombotic agents-lessons after 1 year. 2021 , 8, e524-e533	77
225	COVID-19 versus SARS: A comparative review. 2021 , 14, 967-977	1
224	Routine Hematological Parameters May Be Predictors of COVID-19 Severity. 2021 , 8, 682843	2
223	COVID-19-related laboratory coagulation findings. 2021 , 43 Suppl 1, 36-42	10
222	The Role of Alveolar Edema in COVID-19. 2021 , 10,	6
221	Clinical Characteristics and Outcome of Patients with Suspected COVID-19 in Emergency Department (RESILIENCY Study II). 2021 , 11,	1
220	Anticoagulants and antiaggregants in the COVID-19 era. 2021 , 58-66	1
219	Cardiovascular system in the sars-CoV-2: impact of therapies. 2021 , 39, 1306-1308	0
218	Efficacy and Safety of Oral Anticoagulants in the Treatment of COVID-19. 2021 , 17, 42-49	
217	Combined Anticoagulant and antiplatelet therapy is associated with an improved outcome in hospitalized COVID-19 patients: a propensity matched cohort study.	
216	COVID-19 Pathogenesis: From Molecular Pathway to Vaccine Administration. 2021 , 9,	1
215	Prevention of Thromboembolic Events in Patients with COVID-19. 2021 , 5, e415-e419	
214	Preventing Thrombohemorrhagic Complications of Heparinized COVID-19 Patients Using Adjunctive Thromboelastography: A Retrospective Study. 2021 , 10,	6
213	The Impact of Risk-Adjusted Heparin Regimens on the Outcome of Patients with COVID-19 Infection. A Prospective Cohort Study. 2021 , 13,	2
212	COVID-19 and coagulopathy. 2021 , 15, 1259-1274	7
211	Thromboprophylaxis strategies to improve the prognosis of COVID-19. 2021 , 139, 106883	3

210	D-dimers: a most misunderstood test. 2021 , 82, 1-5		
209	Spontaneous Muscle Hematoma in Patients with COVID-19: A Systematic Literature Review with Description of an Additional Case Series. 2021 ,		6
208	Venous thromboembolism in patients with COVID-19 infection: risk factors, prevention, and management. 2021 , 34, 101-116		2
207	Evaluation of a patient specific, targeted-intensity pharmacologic thromboprophylaxis protocol in hospitalized patients with COVID-19. 2021 , 1		2
206	Disseminated intravascular coagulation and its immune mechanisms. 2021 ,		0
205	Thromboprophylaxis in Patients with COVID-19: Systematic Review of National and International Clinical Guidance Reports. 2021 ,		3
204	Colon perforation as a complication of COVID-19: a case report. 2021 , 7, 175		2
203	[Title: Covid-19-associated coagulopathy]. 2021 , 146, 944-949		
202	Thromboprophylaxis in COVID-19: Early initiation might be as important as optimal dosing. 2021 , 204, 134-135		5
201	Nuts and bolts of COVID-19 associated coagulopathy: the essentials for management and treatment. 2021 , 133, 899-911		2
200	Alternative Management Of Cushing's Syndrome During Covid-19 Pandemic. 2021 , 02,		
199	Safety and efficacy of different prophylactic anticoagulation dosing regimens in critically and non-critically ill patients with COVID-19: A systematic review and meta-analysis of randomized controlled trials. 2021 ,		14
198	Better Anticoagulated Than Not! Hypercoagulability in COVID-19. 2021 , 17, 522-523		
197	A Systematic Review and a Meta-Analysis Comparing Prophylactic and Therapeutic Low Molecular Weight Heparins for Mortality Reduction in 32,688 COVID-19 Patients. 2021 , 12, 698008		4
196	American Society of Hematology living guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19: May 2021 update on the use of intermediate-intensity anticoagulation in critically ill patients. <i>Blood Advances</i> , 2021 , 5, 3951-3959	7.8	12
195	COVID-19 Critical Illness: A Data-Driven Review. 2021 ,		3
194	Transient acquired factor XII deficiency associated with moderately severe Covid-19 pneumonia. 2021 , 43, 515-517		2
193	Apixaban, an orally available anticoagulant, inhibits SARS-CoV-2 replication by targeting its major protease in a non-competitive way.		

192	Implications of Evolving Guidelines for Coagulopathy and Thrombosis Management in COVID-19. 2021 , 17, 524-526		
191	Interdisciplinary Approach to Thrombosis Management in COVID-19 at a Large Academic Center. 2021 , 17, 517-521		2
190	Heparin-induced thrombocytopenia in patients with COVID-19: a systematic review and meta-analysis. <i>Blood Advances</i> , 2021 , 5, 4521-4534	7.8	3
189	Philadelphia-Negative Myeloproliferative Neoplasms Around the COVID-19 Pandemic. 2021 , 16, 455-463		1
188	Risk factors for transfer from Respiratory Intermediate Care Unit to Intensive Care Unit in COVID-19. 2021 , 59, 602-607		3
187	Business Not As Usual: Implementation Strategies That Support Learning During the COVID-19 Pandemic. 2021 , 5, 1008-1011		
186	Evaluation of the efficacy of anticoagulation therapy in reducing mortality in a nationwide cohort of hospitalized patients with coronavirus disease in Japan. 2021 , 112, 111-116		1
185	Catastrophic Concomitant Arterial and Venous Thrombosis in a Mild COVID-19-Positive Patient.		
184	Review of COVID-19, part 2: Musculoskeletal and neuroimaging manifestations including vascular involvement of the aorta and extremities. 2021 , 79, 300-313		2
183	Anticoagulation for COVID-19 Patients: A Bird's-Eye View. 2021 , 27, 10760296211039288		2
182	Current Status of Anticoagulation for Hospitalized Patients with Coronavirus Disease 2019 (COVID-19). 2021 , 3, 125		
181	Prevention of venous thromboembolism in COVID-19 patients: Is there a way forward?. 2021 , 4, 83		0
180	COVID-19 hospital prevalence as a risk factor for mortality: an observational study of a multistate cohort of 62 hospitals. 2021 ,		2
179	The Saudi Critical Care Society practice guidelines on the management of COVID-19 in the ICU: Therapy section. 2021 ,		2
178	Therapeutic vs. prophylactic bempiparin in hospitalized patients with non-severe COVID-19 (BEMICOP): an open-label, multicenter, randomized trial. 2021 ,		10
177	Top 10 acral skin manifestations associated with COVID-19: A scoping review. 2021 , 34, e15157		0
176	Complications of critical COVID-19: Diagnostic and therapeutic considerations for the mechanically ventilated patient. 2021 ,		4
175	Incidental diagnosis of a large cardiac thrombus swinging through an interatrial communication in a COVID-19 patient: Case report and literature review. 2021 , 71, 102967		0

174	Combined anticoagulant and antiplatelet therapy is associated with an improved outcome in hospitalised patients with COVID-19: a propensity matched cohort study. 2021 , 8,		2
173	Timing of venous thromboembolism diagnosis in hospitalized and non-hospitalized patients with COVID-19. 2021 , 207, 150-157		4
172	Incidence and Predictors of Thrombotic Complications in 4742 Patients with COVID-19 or Other Acute Infectious Respiratory Diseases: A Propensity Score-Matched Study. 2021 , 10,		1
171	Descriptive analysis of Acute Ischemic stroke in COVID-19 patients through the course of the COVID-19 pandemic. 2021 ,		2
170	Characteristics and treatment of coagulopathy associated with COVID-19. 2021 , 72, 70-77		
169	Dilemma of Anticoagulation Therapy in Mild or Asymptomatic COVID-19 Cases.. 2021 , 13, e19291		1
168	American Society of Hematology living guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19: July 2021 update on post-discharge thromboprophylaxis. <i>Blood Advances</i> , 2021 ,	7.8	14
167	Heparin and Derivatives for Advanced Cell Therapies. 2021 , 22,		2
166	Gastrointestinal bleeding and endoscopic findings in critically and non-critically ill patients with corona virus disease 2019 (COVID-19): Results from Lean European Open Survey on SARS-CoV-2 (LEOSS) and COKA registries. 2021 , 9, 1081-1090		5
165	Virchow's Triad and the Role of Thrombosis in COVID-Related Stroke. 2021 , 12, 769254		2
164	Arterial and Venous Thrombosis Complicated in COVID-19: A Retrospective Single Center Analysis in Japan. 2021 , 8, 767074		5
163	Management of Pulmonary Thromboembolism.		0
162	Intermediate-to-therapeutic versus prophylactic anticoagulation for coagulopathy in hospitalized COVID-19 patients: a systemic review and meta-analysis. 2021 , 19, 91		2
161	Therapeutic-dose heparin should integrate the standard of care of moderately ill patients with COVID-19 admitted to hospital.. 2022 , 43, 365-366		
160	Novel Coronavirus Infection (COVID-19) Related Thrombotic and Bleeding Complications in Critically Ill Patients: Experience from an Academic Medical Center. 2021 , 10,		1
159	Coronavirus disease 2019 and cardiovascular diseases: collateral damage?. 2021 , 35,		1
158	Hormonal Contraception and Massive Pulmonary Embolism in a COVID-19 Ambulatory Patient: A Case Report.. 2021 , 11, 914-918		2
157	Coronavirus Disease 2019: Clinics, Treatment, and Prevention. 2021 , 12, 761887		6

156	Prevention and management of thrombosis in hospitalised patients with COVID-19 pneumonia. 2021,	10
155	Anticoagulation in COVID-19: a review of current literature and guidelines. 2021, 1-18	3
154	Enoxaparin for thromboprophylaxis in hospitalized COVID-19 patients: comparison of 40 mg o.d. vs 40 mg b.i.d. The X-COVID19 Randomized Clinical Trial.	1
153	COVID-19: The Impact on Cardiovascular System. 2021, 9,	0
152	Thrombotic and Hemorrhagic Incidences in Patients After Discharge from COVID-19 Infection: A Systematic Review and Meta-Analysis.. 2021, 27, 10760296211069082	1
151	Pharmacological Agents Targeting Coagulopathy in COVID-19: A Review. 2021, 315-331	
150	Low in-hospital mortality rate in patients with COVID-19 receiving thromboprophylaxis: data from the multicentre observational START-COVID Register.. 2022, 1	1
149	Molecular mechanisms of hemostasis activation in COVID-19 at the hospital stage. 2021, 10, 25	
148	Acute myocardial injury in patients with COVID-19: Possible mechanisms and clinical implications.. 2022, 10, 762-776	1
147	A Comparison and Evaluation of International Guidelines on the Treatment of Severe SARS-CoV-2 Infection.. 2022,	
146	Pathomechanisms and Treatment Implications for Stroke in COVID-19: A Review of the Literature.. 2022, 12,	1
145	Prothrombotic Milieu, Thrombotic Events and Prophylactic Anticoagulation in Hospitalized COVID-19 Positive Patients: A Review.. 2022, 28, 10760296221074353	2
144	Upper extremity deep vein thrombosis in COVID-19: Incidence and correlated risk factors in a cohort of non-ICU patients.. 2022, 17, e0262522	0
143	Thromboembolic complications during and after hospitalization for COVID-19: Incidence, risk factors and thromboprophylaxis. 2022, 6, 100096	0
142	Treatment Options in CoViD19. 2022, 63-94	
141	Comparison Between Standard Vs. Escalated Dose Venous Thromboembolism (VTE) Prophylaxis in Critically Ill Patients with COVID-19: A Two centers, Observational Study.. 2022,	0
140	Thromboprophylaxis in Patients with COVID-19. A Brief Update to the CHEST Guideline and Expert Panel Report.. 2022,	6
139	Pentosan polysulfate inhibits attachment and infection by SARS-CoV-2 in vitro: insights into structural requirements for binding.	0

138	Heparin and SARS-CoV-2: Multiple Pathophysiological Links.. 2021 , 13,	1
137	The hemotological profile in COVID-19 infection: A mini-review. 2021 , 12, 39	
136	Report of Low Incidence of Thrombosis with Early Prophylaxis in Hospitalized Patients with COVID-19 from Two Saudi Tertiary Centers.. 2022 , 28, 10760296221086286	1
135	Clinical Approaches to the COVID-19 Pandemic. 2022 , 1-21	
134	COVID-19 in the Critically Ill Patient. 2022 ,	0
133	Coronavirus disease 2019 in Saudi Arabia: A nationwide real-world characterization study. 2022 ,	
132	Anticoagulants for people hospitalised with COVID-19.. 2022 , 3, CD013739	3
131	Impact of Thromboprophylaxis Intensity on Patients' Mortality Among Hospitalized Patients with COVID-19: A Propensity-Score Matched Study.. 2022 , 14, 361-368	0
130	Using Explicit Thresholds for Benefits and Harms in partially contextualized GRADE Guidelines. Pilot experience from a living COVID-19 guideline.. 2022 ,	
129	Anticoagulation in Patients With COVID-19: JACC Review Topic of the Week.. 2022 , 79, 917-928	3
128	Coagulation factors directly cleave SARS-CoV-2 spike and enhance viral entry.. 2022 , 11,	4
127	[Effectiveness of thromboprophylaxis with low molecular weight heparin in critically ill patients with COVID-19. An observational, prospective, multicenter study.]. 2022 ,	1
126	Elucidating the Correlation of D-Dimer Levels with COVID-19 Severity: A Scoping Review.. 2022 , 2022, 9104209	0
125	Endothelial Dysfunction in COVID-19: A Unifying Mechanism and a Potential Therapeutic Target.. 2022 , 10,	6
124	Severe COVID-19 Infection Management in a Patient with Mild Haemophilia-A Case Report.. 2022 , 14, 103-107	1
123	The role of heparin in reducing in-hospital complications and three-month mortality rates in hospitalized COVID-19 patients.. 2022 ,	
122	The ecosystem of health decision making: from fragmentation to synergy.. 2022 , 7, e378-e390	0
121	Prophylactic anticoagulants for non-hospitalised people with COVID-19. 2022 , 2022,	0

120	Persistent Lung Injury and Prothrombotic State in Long COVID.. 2022 , 13, 862522	1
119	Intensive-Dose Tinzaparin in Hospitalized COVID-19 Patients: The INTERACT Study.. 2022 , 14,	1
118	Implementation of Clinical Practice Guidelines for Hospitalized Patients With COVID-19 in Academic Medical Centers.. 2022 , 5, e225657	
117	Influence of sex on development of thrombosis in patients with COVID-19: From the CLOT-COVID study.. 2022 , 213, 173-178	1
116	Clinical update on COVID-19 for the emergency and critical care clinician: Medical management.. 2022 , 56, 158-170	2
115	Bilateral renal infarction with COVID-19 pneumonia: a case report.. 2021 , 2021, omab121	1
114	Pre- and in-hospital anticoagulation therapy in coronavirus disease 2019 patients: a propensity-matched analysis of in-hospital outcomes. 2021 , 23,	2
113	Comparison of Higher-Than-Standard to D-Dimer Driven Thromboprophylaxis in Hospitalized Patients With COVID-19. 001857872110664	0
112	Risk Factors for Venous Thromboembolism in Severe COVID-19: A Study-Level Meta-Analysis of 21 Studies.. 2021 , 18,	4
111	COVID-19 and thrombosis: searching for evidence. 2021 , 2021, 621-627	3
110	Enoxaparin for thromboprophylaxis in hospitalized COVID-19 patients: The X-COVID-19 Randomized Trial.. 2021 , e13735	4
109	MPN and thrombosis was hard enough .□□ now there's COVID-19 thrombosis too. 2021 , 2021, 710-717	0
108	How to recognize and manage COVID-19-associated coagulopathy. 2021 , 2021, 614-620	4
107	Splanchnic venous thrombosis in a nephrotic patient following COVID-19 infection: a case report.. 2021 , 22, 420	4
106	[Neurological Manifestations of COVID-19]. 2021 , 89, 637-650	
105	Aspirin as an Adjunctive Pharmacologic Therapy Option for COVID-19: Anti-Inflammatory, Antithrombotic, and Antiviral Effects All in One Agent.. 2021 , 13, 957-970	0
104	Gut in COVID 19-is it worth noticing.. 2021 , 30, S267-S269	0
103	Mild COVID-19 illness as a Risk Factor for Venous Thromboembolism. 2021 , 13, e18236	1

102	Pentosan polysulfate inhibits attachment and infection by SARS-CoV-2 in vitro: insights into structural requirements for binding.. 2022,			2
101	Low Molecular Weight Heparin Doses and Ventilator Airway Necessity in the COVID-19 Patients: Systematic Review and Meta-analysis. 2022, 10, 241-245			
100	Implications of COVID-19 on Thrombotic Profile of Severely Affected Patients.. 2022, 1-11			
99	Preinfection Anticoagulation/Antiplatelet Therapy Does Not Influence the Outcome of COVID-19 Disease in Hospitalized Patients.. 2022,			
98	Exposure and Outcome in practice: a retrospective cohort study between fibrinolytic suppression and hypercoagulability, the severity of hypoxemia, and mortality in COVID-19 patients.. 2022,			0
97	Clinical features of thrombosis and bleeding in COVID-19.. 2022,			2
96	Thromboembolic Events in Deceased Patients with Proven SARS-CoV-2 Infection: Frequency, Characteristics and Risk Factors.			
95	Anti-Inflammatory Effects and Decreased Formation of Neutrophil Extracellular Traps by Enoxaparin in COVID-19 Patients.. 2022, 23,			1
94	Implications of COVID-19 to stroke medicine: an epidemiological and pathophysiological perspective.. 2022, 20,			
93	[Viral pneumonia. COVID-19 pneumonia].. 2022, 13, 3224-3234			
92	A case of severe COVID-19 with pulmonary thromboembolism related to heparin-induced thrombocytopenia during prophylactic anticoagulation therapy.. 2022,			1
91	Venous thromboembolism in COVID-19 patients and prediction model: a multicenter cohort study.. 2022, 22, 462			2
90	American Society of Hematology living guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19: January 2022 update on the use of therapeutic-intensity anticoagulation in acutely ill patients.. <i>Blood Advances</i> , 2022,	7.8		6
89	Double Trouble: A Case of Two Simultaneous Thrombotic Events in a Patient With COVID-19. 2022,			
88	Optimal thromboprophylaxis strategies in non-critically ill patients with COVID-19 pneumonia. The PROTHROMCOVID Randomized Controlled Trial.			1
87	Assessment of Bleeding Risk in Hospitalized COVID-19 Patients: A Tertiary Hospital Experience during the Pandemic in a Predominant Minority PopulationBleeding Risk Factors in COVID-19 Patients. 2022, 11, 2754			
86	[Systemic and extrapulmonary manifestations of COVID-19].. 2022, 13, 3235-3245			
85	Erkrankungen der Mutter während der Schwangerschaft. 2022, 3, 70-79			

84	Platelet and extracellular vesicles in COVID-19 infection and its vaccines. 2022 , 103459		0
83	Society of Family Planning Clinical Recommendations: Contraceptive Care in the Context of Pandemic Response. 2022 ,		0
82	Prophylactic Anticoagulation and Thrombosis in Hospitalized Patients with Clinically Stable COVID-19 at Admission: From the CLOT-COVID Study.		
81	The Incidence and Impact of In-Hospital Bleeding in Patients with Acute Coronary Syndrome during the COVID-19 Pandemic. 2022 , 11, 2926		1
80	The Role of Heparin in COVID-19: An Update after Two Years of Pandemics. 2022 , 11, 3099		2
79	Prophylactic Anticoagulant Use and Adverse Events with Bleeding in Critically Ill COVID-19 Patients. 2022 , 39, 146-157		
78	Safety and Efficacy Analysis of Apixaban Compared to Heparins in Hospitalized Non-Critically Ill COVID-19 Patients. 001857872210957		0
77	Utility of Thromboelastography and velocity curve derivative in diagnosing COVID -19 associated coagulopathy.		
76	Anticoagulation in Hospitalized Patients with COVID-19.		0
75	Therapeutic-Dose vs. Prophylactic-Dose Anticoagulation Therapy for Critically Ill Patients With COVID-19 in a Practice-Based Observational Study. 2022 ,		1
74	Therapeutic anticoagulation using heparin in early phase severe coronavirus disease 2019: A retrospective study. 2022 , 58, 84-88		
73	COVID-19 and Thrombosis: Pathophysiological Mechanisms and Therapeutic Update.		0
72	American Society of Hematology living guidelines on the use of anticoagulation for thromboprophylaxis in patients with... <i>Blood Advances</i> ,	7.8	4
71	Acute Myocardial Infarction From Embolized Left Ventricular Thrombus in Coronavirus Disease 2019. 2022 ,		
70	COVID Coagulopathy and Thrombosis: A Systematic Review. 2022 , 18, 78		
69	Experience with the use of combination antithrombotic therapy in a patient with acute coronary syndrome and underlying severe coronavirus infection. 2022 , 12, 60-68		
68	High-dose versus low-dose venous thromboprophylaxis in hospitalized patients with COVID-19: a systematic review and meta-analysis.		2
67	Apixaban, an orally available anticoagulant, inhibits SARS-CoV-2 replication and its major protease in a non-competitive way.		1

66	International electronic health record-derived post-acute sequelae profiles of COVID-19 patients. 2022 , 5,		1
65	Special Issue "COVID-19 and Venous Thromboembolism" 2022 , 11, 3822		
64	3D-PAST: Risk Assessment Model for Predicting Venous Thromboembolism in COVID-19. 2022 , 11, 3949		1
63	A Framework for the Development of Living Practice Guidelines in Health Care. <i>Annals of Internal Medicine</i> ,	8	0
62	Bleeding and thrombotic complications in patients with severe COVID-19: A prospective observational study. <i>Health Science Reports</i> , 2022 , 5,	2.2	1
61	An Insight Into Pathophysiology, Epidemiology, and Management of Cardiovascular Complications of SARS-CoV-2 Infection, Post-acute COVID Syndrome, and COVID Vaccine. 2022 , 21, 123-129		
60	Nanoscale Technologies in the Fight against COVID-19: From Innovative Nanomaterials to Computer-Aided Discovery of Potential Antiviral Plant-Derived Drugs. 2022 , 12, 1060		0
59	The therapeutic relevance of the Kallikrein-Kinin axis in SARS-cov-2-induced vascular pathology. 1-16		0
58	A comparison of three thromboprophylaxis regimens in critically ill COVID-19 patients: An analysis of real-world data. 9,		
57	Coronavirus Disease 2019-Associated Coagulopathy. 2022 , 10, 1556		1
56	Hyperkalemia: do you forget something?.		
55	Low molecular weight heparin is associated with better outcomes than unfractionated heparin for thromboprophylaxis in hospitalized COVID-19 patients: a meta-analysis.		0
54	Thromboembolic events in COVID-19 ambulatory patients: An observational study about incidence, and thromboprophylaxis outcomes. 2022 , 17, e0270195		0
53	Occurrence of Thromboembolic Events and Mortality Among Hospitalized COVID-19 Patients: Large Observational Cohort Study of Electronic Health Records.		1
52	Thromboembolic events in deceased patients with proven SARS-CoV-2 infection: Frequency, characteristics and risk factors. 2022 , 218, 171-176		1
51	Significant Impact of Age on Mortality and Non-significant Impact of Age on Thrombosis and Major Bleeding in Patients with COVID-19: From the CLOT-COVID Study. 2022 ,		1
50	Pathophysiology and Management of Hypercoagulation in Infectious Diseases. 2022 , 06, 131-140		1
49	Thrombosis after SARS-CoV2 infection or COVID-19 vaccination: will a nonpathologic anti-PF4 antibody be a solution?A narrative review. 2022 , 5, 97-103		0

48	Approach to Thromboprophylaxis for Prevention of Venous Thromboembolism in COVID-19: Global Updates and Clinical Insights from India. 2022 , 12, 766-781	0
47	Efficacy and Safety of Tinzaparin in Prophylactic, Intermediate and Therapeutic Doses in Non-Critically Ill Patients Hospitalized with COVID-19: The PROTHROMCOVID Randomized Controlled Trial. 2022 , 11, 5632	0
46	The Case for Therapeutic-Intensity Anticoagulation in Patients with COVID-19-Associated Moderate Illness.	0
45	Higher Dose Anticoagulation Cannot Prevent Disease Progression in COVID-19 Patients: A Systematic Review and Meta-Analysis. 2022 , 10, 2194	0
44	SARS-CoV-2 antibody research in patients with unprovoked pulmonary embolism in COVID-19 pandemic period.	0
43	Long peripheral cannula in COVID-19 patients: 769 catheter days experience from a semi-intensive respiratory COVID unit. 112972982211150	0
42	Strength of Anticoagulation in Moderate to Severe COVID-19 Illness: In Medio Stat Virtus?.	0
41	Incidence, risk factors, and clinical impact of major bleeding in hospitalized patients with COVID-19: a sub-analysis of the CLOT-COVID Study. 2022 , 20,	1
40	Knowledge gaps for prophylactic antithrombotic agents use in patients with COVID-19: Insights on new variants, vaccination and emerging antivirals.	0
39	Current practices in pediatric hospital-acquired thromboembolism: Survey of the Children's Hospital Acquired Thrombosis (CHAT) Consortium. 2022 , 6,	0
38	Thrombosis-Related Loss of Arterial Lines in the First Wave of COVID-19 and NonCOVID-19 Intensive Care Unit Patients. Publish Ahead of Print,	0
37	COVID-19-Associated Pulmonary Embolism: Review of the Pathophysiology, Epidemiology, Prevention, Diagnosis, and Treatment.	0
36	Drugs for the prevention and treatment of COVID-19 and its complications: An update on what we learned in the past 2 years. 13,	1
35	Therapeutic advances in COVID-19.	4
34	Practical Recommendations for Optimal Thromboprophylaxis in Patients with COVID-19: A Consensus Statement Based on Available Clinical Trials. 2022 , 11, 5997	2
33	Evaluation of a fast-and-frugal clinical decision algorithm (Pathways) on clinical outcomes in hospitalised patients with COVID-19 treated with anticoagulants.	0
32	Extreme obesity is a strong predictor for in-hospital mortality and the prevalence of long-COVID in severe COVID-19 patients with acute respiratory distress syndrome. 2022 , 12,	2
31	Assessment of Healthcare Resource Utilization by Anticoagulant Heparinoid Dosage Level in Patients Hospitalized with COVID-19. 2022 , 28, 107602962211378	0

30	Coagulation Abnormalities in Patients with COVID-19. 2022 , 141-156	○
29	Therapeutic considerations for prevention and treatment of thrombotic events in COVID-19. 2022 , 100126	○
28	Gene variants in pro-coagulant and anti-coagulant genes could be prognostic genetic markers of COVID-19 susceptibility. 2022 , 8, e11536	○
27	COVID-19 related peripheral arterial thrombotic events in intensive care unit and non-intensive care unit patients: A retrospective case series. 170853812211401	○
26	COVID-19 IN PATIENTS WITH MYELOPROLIFERATIVE NEOPLASMS: THE RISK OF THROMBOEMBOLIC EVENTS AND CURRENT OPTIONS FOR ANTITHROMBOTIC PROPHYLAXIS. 2022 , 4, 88-103	○
25	The Role of VV-ECMO in Severe COVID-19 ARDS.	○
24	Clinical/biochemical characteristics and related outcomes in people with new-onset diabetes and COVID -19: experience from a single centre. 2022 , 39, 24-31	1
23	Coexistence of Intramuscular Hematoma in Patients with a Diagnosis of COVID-19. 2022 , 38, 288-294	○
22	Real-World Management of Pharmacological Thromboprophylactic Strategies for COVID-19 Patients in Japan. 2022 , 2, 897-907	1
21	Acute Vascular Injury in COVID-19. 2022 , 151-170	○
20	Drug-drug interaction between dexamethasone and direct-acting oral anticoagulants: a nested case-control study in the National COVID Cohort Collaborative (N3C). 2022 , 12, e066846	○
19	COVID-19: Radiologic Diagnosis. 2023 , 61-100	○
18	Efficacy and safety of two heparin regimens for prevention of venous thromboembolism in hospitalized patients with COVID-19: a meta-analysis.	○
17	Enoxaparin Posology According to Prothrombotic Status and Bleeding Risk in Hospitalized Patients with SARS-CoV-2 Pneumonia. 2023 , 12, 928	○
16	Evaluation of antithrombotic prophylaxis and thrombotic events in children with COVID-19 or MIS-C: A tertiary pediatric center experience. 2023 ,	○
15	Thromboembolic Events in COVID-19. 2022 , 201-216	○
14	Incidence of lower limb deep vein thrombosis in patients with COVID-19 pneumonia through different waves of SARS-CoV-2 pandemic: A multicenter prospective study. 2023 , 18, e0280247	○
13	Thrombosis and Anticoagulation Strategies in Patients with COVID-19 Including Japanese Perspective. 2023 , 30, 311-320	○

- 12 Pharmacology of Heparin and Related Drugs: An Update. **2023**, 75, 328-379 1
- 11 Antithrombotic therapy in patients with COVID-19: indications, pharmacotherapy and controversy. svn-2023-002321
- 10 Effectiveness of thromboprophylaxis with low molecular weight heparin in critically ill patients with COVID-19. An observational prospective, multicenter study. **2023**, 70, 129-139 0
- 9 COVID-19 and the Response to Antiplatelet Therapy. **2023**, 12, 2038 0
- 8 Assessment of the Risk of Venous Thromboembolism in Nonhospitalized Patients With COVID-19. **2023**, 6, e232338 0
- 7 Retrospective Study of Thrombosis in Hospitalized Patients with COVID-19 in Rural North Carolina. **2023**, 84, 0
- 6 An evolving understanding of the basis and management of vascular complications of COVID-19: Where do we go from here?. **2023**, 0
- 5 Pulmonary Manifestations of COVID-19. **2024**, 100-136 0
- 4 Anticoagulation strategy and safety in critically ill COVID-19 patients: a French retrospective multicentre study. **2023**, 21, 0
- 3 Predictors of Pulmonary Embolism in Hospitalized Patients with COVID-19. 0
- 2 Therapeutic strategies for COVID-19: progress and lessons learned. 0
- 1 Antiphospholipid antibodies in convalescent plasma of donors recovered from mild COVID -19 infection. 0